The losartan renal protecion study - rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with Angiotensin II Antagonist Losartan). - Brenner,B.M.; Cooper,M.E.; Zeeuw Dd,D.; Grunfeld,J.P.; Keane,W.F.; Kurokawa,K.; MCGill,J.B.; Mitch,W.E.; Parving,H.H.; Remuzzi,G.; Ribeiro,A.B.; Schluchter,M.D.; et al. (J Renin Angiotensin Aldosterone Syst, 2000)